References
- Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans. Platelets 2006; 17: 209–217
- Drummer OH, Routley L, Christophidis N. Reversibility of disulfide formation: Comparison of chemical and enzyme-mediated reduction of penicillamine and captopril disulfides. Biochemical Pharmacology 1987; 36: 1197–1201
- Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, Pang H. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2007a; 21: 169–179
- Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metabolism and Disposition 2007b; 35: 1096–1104
- Hagihara K, Kurihara A, Kawai K, Kazui M, Takahashi M, Kawabata K, Farid NA, Ikeda T. Absorption, distribution, and excretion of a new thienopyridine agent prasugrel in rats. Xenobiotica 2007; 37: 788–801
- Ikeda T, Iwabuchi H, Kawabata K, Tsutsumi S, Suzuki N, Sone J, Yoneda K, Kita J. Pharmacokinetics and disposition of CS-747, a new pro-drug ADP-receptor antagonist, in rats and dogs. 1999, Thrombosis and Haemostasis 82(Suppl):829. Abstract 2627
- Iyer RA, Mitroka J, Malhotra B, Bonacorsi S, Waller SC, Rinehart JK, Roongta VA, Kripalani K. Metabolism of [14C]omapatrilat, a sulphydryl-containing vasopeptidase inhibitor in humans. Drug Metabolism and Disposition 2001; 29: 60–69
- Madan A, Faiman MD. NADPH-dependent, regioselective S-oxidation of a thionosulfur- and thioether-containing xenobiotic, diethyldithiocarbamate methyl ester by rat liver microsomes. Drug Metabolism and Disposition 1994; 22: 324–330
- Madan A, Williams TD, Faiman MD. Glutathione and glutathions-S-transferase-dependent oxidative desulfuration of the thione xenobiotic diethyldithiocarbamate methyl ester. Molecular Pharmacology 1994; 46: 1217–1225
- Ortiz de Montellano PR. The cytochrome P450 oxidative system. Handbook of drug metabolism, TF Woolf. Mercel Dekker, Inc., New YorkBasel 1999; 124–126
- Rehmel JLF, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metabolism and Disposition 2006; 34: 600–607
- Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, Koike H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. British Journal of Pharmacology 2001; 132: 47–54